Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) and Evolus (NASDAQ:EOLS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Ono Pharmaceutical and Evolus, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ono Pharmaceutical | 0 | 1 | 0 | 0 | 2.00 |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
Evolus has a consensus target price of $15.00, indicating a potential upside of 115.39%. Given Evolus’ stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Ono Pharmaceutical.
Profitability
This table compares Ono Pharmaceutical and Evolus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ono Pharmaceutical | 15.02% | 9.77% | 7.63% |
| Evolus | -10.85% | N/A | -13.00% |
Institutional and Insider Ownership
90.7% of Evolus shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Ono Pharmaceutical and Evolus”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ono Pharmaceutical | $3.43 billion | 2.04 | $436.04 million | $1.05 | 14.19 |
| Evolus | $316.49 million | 1.45 | -$51.64 million | ($0.52) | -13.39 |
Ono Pharmaceutical has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Ono Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Ono Pharmaceutical has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Summary
Ono Pharmaceutical beats Evolus on 8 of the 14 factors compared between the two stocks.
About Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
